Apremilast
Brand name: Otezla
Rank #65 of 500 drugs by total cost
$283.9M
Total Cost
59,020
Total Claims
$283.9M
Total Cost
2,774
Prescribers
$4,811
Cost per Claim
496
Beneficiaries
61,937
30-Day Fills
$102K
Avg Cost/Provider
21
Avg Claims/Provider
About Apremilast
Apremilast (sold as Otezla) was prescribed 59,020 times by 2,774 Medicare Part D providers in 2023, costing the program $283.9M. At $4,811 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
| 67 | Selexipag (Uptravi) | $279.1M | 12,320 |
| 68 | Liraglutide (Victoza 3-Pak) | $273.0M | 189,358 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology